David Zaccardelli, Verona Pharma CEO

Verona’s COPD drug shines in PhI­II study, po­ten­tial­ly clear­ing path to FDA — shares jump

UK-based Verona Phar­ma’s COPD drug, en­sifen­trine, has suc­ceed­ed in its Phase III tri­al, paving the way for a pos­si­ble FDA ap­proval.

In Verona’s Phase III EN­HANCE-2 study, rough­ly 800 pa­tients with mod­er­ate to se­vere COPD re­ceived en­sifen­trine or place­bo through a neb­u­liz­er twice a day for 24 weeks. At 12 hours post-treat­ment on week 12, the place­bo-cor­rect­ed change in forced ex­pi­ra­to­ry vol­ume (FEV1) — a stan­dard mea­sure of lung func­tion that tests how much breath one can force­ful­ly ex­hale in one sec­ond — was 94 mL, lead­ing the tri­al to meet its pri­ma­ry end­point.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.